Deacetylase inhibitor
![Histone Deacetylase Inhibitor Valproic Acid and Cancer [Retracted]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)
Histone Deacetylase Inhibitor Valproic Acid and Cancer [Retracted]
... histone deacetylase inhibitor displayed anti-tumor activitie in many different types of cancers ...HDAC inhibitor to suppress HDAC4 and induce acetylation of histone H4 by which induces cell growth ...
8
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
... methylation inhibitor and a HDAC inhibitor for gene re-expression [35] led us to explore the effect of hydralazine plus valp- roic acid on global gene ...methylation inhibitor 5-aza-2'-deoxycytidine ...
9
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
... To our knowledge, this is the first report testing HDAC inhibition in concert with conventional chemotherapy in a PDX model derived from patients with high grade ser- ous ovarian cancer. We believe this model has note- ...
8
Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
... HDAC inhibitor VPA and the MTOR inhibitor temsirolimus, both at a clinically achievable concentration [19,20], interacted synergistically to inhibit BL cell ...
11
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
... PPP3CA is a common target of panobinostat and bortezomib. Next, we examined whether the PPP3CA reduction induced by panobinostat is relevant to the clinical effect that panobinostat adds to bortezomib therapy (1, 2). We ...
18
Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
... HDAC inhibitor ITF2357 in eight pa- tients with autoinflammatory disorders (four patients with Schnitzler syndrome, three with HIDS and one with TRAPS), the effect of the drug was disappointing compared with ...
6
Improvement of mouse cloning using nuclear transfer derived embryonic stem cells and/or histone deacetylase inhibitor
... an inhibitor of classes I and IIa/b HDACs but is greater than 10-fold more active against HDAC3 (class I) and HDAC6 (class IIb) than the other HDACs (Blackwell et ...an inhibitor for classes I and IIa HDACs ...
9
The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and rapid upregulation of gadd45β in LS174T human colon cancer cells
... Histone deacetylase (HDAC) inhibitors are consid- ered as promising therapeutic agents against several malignant diseases because they inhibit cancer cell ...HDAC inhibitor, trichostatin A (TSA), on the ...
8
Targeting triple negative breast cancer cells with the histone deacetylase inhibitor panobinostat
... MDA-MB-231 cells (10 5 cells/well) were plated over- night in six-well plates and then treated for 24 hours with panobinostat (100 nM) or vehicle control. Five volumes of ice-cold lysis buffer (20 mM Tris-HCl, pH 7.5/150 ...
15
Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma
... In one of our previous studies, we have shown that panobinsotat levels could achieved 200 nM in the brain following a single 20 mg/kg intraperitoneal (i.p.) dose [36]. Panobinostat also has been tested in clinical II ...
11
Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma
... Histone deacetylase inhibitors are currently under investigation for their therapeutic value in a variety of ...histone deacetylase inhibitors to have synergistic activity with existing therapeutic agents ...
12
STEROIDAL HYDROXAMICACID DERIVATIVES: A STRUCTURALLY NOVEL CLASS OF HDAC INHIBITORS
... histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen ...
6
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
... pan-histone deacetylase inhibitor, has demonstrated meaningful efficacy and a favorable toxicity profile in two single-arm Phase II trials on 153 patients with relapsed/refractory ...
7
HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma
... Background: Histone deacetylation, a common hallmark in malignant tumors, strongly alters the transcription of genes involved in the control of proliferation, cell survival, differentiation and genetic stability. We have ...
6
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
... Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, ...
10
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
... histone deacetylase inhibitor (HDACi) panobinostat leads to degradation of the A/E9a fusion protein, cell cycle arrest, differentiation of AML blasts into mature granulocytes and prolonged ...
7
Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors
... We showed that CAV-2 vectors induced a lower innate re- sponse than HAd5 vectors, based on TNF- ␣ secretion and acute cellular infiltration in the mouse lung. It would be ad- vantageous to limit further the ...
10
Challenging issues in molecular-targeted therapy
... were evaluable for toxicity and 15 for responses. Primary sites included cervix (3), breast (3), lung (1), testis (1), and ovarian (7) carcinomas. The results showed 26.7% PRs and 53% SDs. The main toxicity was ...
8
Application of selective methods in the search for new bioactive natural products from fungi
... Histone Deacetylase Inhibitor II A 22 mM Histone Deacetylase Inhibitor II CALBIOCHEM stock solution was prepared in methanol and diluted to give final concentrations of 0.8, 0.4 and 0.2 [r] ...
301
Innovations in the quantitative virus outgrowth assay and its use in clinical trials
... histone deacetylase inhibitor romidepsin, an HIV vaccine, and recombinant human GM-CSF has achieved a statistically significant reduction on the size of the latent reservoir as measured by total HIV DNA and ...
6